Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | N/A | +105.13% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.16 | N/A | +105.13% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting a focus on partnerships and future growth. However, they did not provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on strategic partnerships and product development.
Ligand Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly, which contributed to a positive stock reaction of 2.72%. The lack of revenue data and guidance may leave investors cautious, but the strong EPS suggests effective cost management and potential for future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALNYLAM PHARMACEUTIC
May 6, 2013